EP1615614A4 - Optimale polyvalente vakzine gegen krebs - Google Patents

Optimale polyvalente vakzine gegen krebs

Info

Publication number
EP1615614A4
EP1615614A4 EP04759415A EP04759415A EP1615614A4 EP 1615614 A4 EP1615614 A4 EP 1615614A4 EP 04759415 A EP04759415 A EP 04759415A EP 04759415 A EP04759415 A EP 04759415A EP 1615614 A4 EP1615614 A4 EP 1615614A4
Authority
EP
European Patent Office
Prior art keywords
cancer
polyvalent vaccine
optimal
optimal polyvalent
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04759415A
Other languages
English (en)
French (fr)
Other versions
EP1615614A2 (de
Inventor
Philip O Livingston
Govindaswami Ragupathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of EP1615614A2 publication Critical patent/EP1615614A2/de
Publication of EP1615614A4 publication Critical patent/EP1615614A4/de
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP04759415A 2003-04-09 2004-04-09 Optimale polyvalente vakzine gegen krebs Ceased EP1615614A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46162203P 2003-04-09 2003-04-09
PCT/US2004/011122 WO2004091507A2 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer

Publications (2)

Publication Number Publication Date
EP1615614A2 EP1615614A2 (de) 2006-01-18
EP1615614A4 true EP1615614A4 (de) 2007-08-22

Family

ID=33299843

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04759415A Ceased EP1615614A4 (de) 2003-04-09 2004-04-09 Optimale polyvalente vakzine gegen krebs

Country Status (4)

Country Link
EP (1) EP1615614A4 (de)
JP (1) JP2006522828A (de)
CA (1) CA2521812A1 (de)
WO (1) WO2004091507A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458242A4 (de) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer Polyvalente konjugatvakzine gegen krebs
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
PL1960434T3 (pl) 2005-12-08 2012-12-31 Squibb & Sons Llc Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1
US9125848B2 (en) 2010-06-10 2015-09-08 The Cleveland Clinic Foundation Alpha lactalbumin immunization methods
WO2013158553A1 (en) 2012-04-16 2013-10-24 The Cleveland Clinic Foundation Multivalent breast cancer vaccine
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
WO2017216098A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Assay and method for determining cdc eliciting antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (en) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (en) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GILEWSKI T ET AL: "Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3270 - 3275, XP002964246, ISSN: 0027-8424 *
KRUG ET AL: "Development of a tetravalent small cell lung cancer (SCLC) vaccine containing GM2, fucosyl GM1, Globo H, and polysialic acid", LUNG CANCER, vol. 41, 1 August 2003 (2003-08-01), pages S47, XP005875064 *
KRUG L.M. ET AL: "Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin", CLINICAL CANCER RESEARCH, vol. 10, no. 3, 1 February 2004 (2004-02-01), pages 916 - 923 *
KRUG LEE M.: "Vaccine therapy for small cell lung cancer", SEMINARS IN ONCOLOGY, vol. 31, no. 1, 1 February 2004 (2004-02-01), pages 112 - 116, XP008098213 *
LIVINGSTON P.: "Current status of cancer vaccines against cell surface antigens on small cell lung cancer.", BIOTECNOLOGIA APLICADA, vol. 19, no. 3-4, 2002, pages 192 *
LIVINGSTON P.: "Immunization of mice with polysialic acid and N-propionylated polysialic acid-KLH conjugates plus QS-21 results in antibodies against human small cell lung cancer cells", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), pages 288, XP008012617 *
PATEL JYOTI D ET AL: "TARGETING LETHAL MINIMAL RESIDUAL DISEASE IN SMALL CELL LUNG CANCER", SEMINARS IN ONCOLOGY, W.B. SAUNDERS,, US, vol. 30, no. 1, February 2003 (2003-02-01), pages 79 - 85, XP008077869, ISSN: 0093-7754 *
RAGUPATHI G ET AL: "Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 7-8, 15 January 2002 (2002-01-15), pages 1030 - 1038, XP004332972, ISSN: 0264-410X *
RAGUPATHI G ET AL: "THE CASE FOR POLYVALENT CANCER VACCINES THAT INDUCE ANTIBODIES", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 1, no. 2, August 2002 (2002-08-01), pages 193 - 206, XP008048224, ISSN: 1476-0584 *
ZHANG SHENGLE ET AL: "Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides", INTERNATIONAL JOURNAL OF CANCER, vol. 73, no. 1, 1997, pages 42 - 49, XP002431043, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
CA2521812A1 (en) 2004-10-28
WO2004091507A2 (en) 2004-10-28
WO2004091507A3 (en) 2005-12-15
JP2006522828A (ja) 2006-10-05
EP1615614A2 (de) 2006-01-18

Similar Documents

Publication Publication Date Title
EP1458242A4 (de) Polyvalente konjugatvakzine gegen krebs
EP1941278A4 (de) Optimaler polyvalenter impfstoff für krebs
GB0417494D0 (en) Vaccine
GB0409940D0 (en) Vaccine
HRP20130407T1 (en) Rotavirus vaccine
GB0329146D0 (en) Vaccine
EP1660636A4 (de) Impfstoffe gegen krebs
EP1667701A4 (de) Tumorvakzine
GB0411150D0 (en) Vaccine
GB0323840D0 (en) Vaccines
EP1615614A4 (de) Optimale polyvalente vakzine gegen krebs
EP1625144A4 (de) Polyvalentes immunogen
GB0305794D0 (en) Vaccine
GB0330079D0 (en) Vaccine
GB0305793D0 (en) Vaccine
GB0321614D0 (en) Vaccines
SI1660123T1 (sl) Cepivo proti rotavirusom
GB0413510D0 (en) Vaccine
GB0304634D0 (en) Vaccines
EP1594899A4 (de) Idiotypischer impfstoff
GB0308691D0 (en) Vaccine preparations
AU2002321882A8 (en) Multivalent synthetic vaccine for cancer
GB0412407D0 (en) Vaccine
PL1618130T3 (pl) Szczepionka terapeutyczna przeciw nowotworom
EP1646282A4 (de) Genetische impfstoffe für die krebstherapie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20051104

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20051221BHEP

Ipc: G01N 33/543 20060101ALI20051221BHEP

Ipc: G01N 33/53 20060101AFI20051221BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070724

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20070713BHEP

Ipc: A61K 39/00 20060101ALI20070713BHEP

Ipc: G01N 33/543 20060101ALI20070713BHEP

Ipc: G01N 33/53 20060101ALI20070713BHEP

Ipc: G01N 33/574 20060101AFI20070713BHEP

17Q First examination report despatched

Effective date: 20071106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100311